|
30.04.2020 08:16:00
|
Medicover: Interim Report January-March 2020
STOCKHOLM, April 30, 2020 /PRNewswire/ --
- Revenue increased by 19.6% to €238.8m (€199.7m). Organic revenue grew by 5.8%.
- Operating profit (EBIT) was €6.4m (€11.3m), representing an operating margin of 2.7% (5.6%).
- Net result amounted to €-2.5m (€6.9m), which represents a net result margin of -1.0% (3.4%).
- EBITDA increased by 5.6% to €29.0m (€27.5m), corresponding to an EBITDA margin of 12.2% (13.8%).
- EBITDAaL was €16.8m (€18.5m), corresponding to an EBITDAaL margin of 7.0% (9.2%).
- Net cash flow from operating activities was €36.5m (€24.1m).
- Basic/diluted loss per share were €-0.006 (earnings €0.046).
- Covid-19 pandemic has a significant impact on operating performance.
REVENUE AND EARNINGS
€ millions (€m) | Q1 2020 | Q1 2019 | Variance | FY 2019 |
Revenue | 238.8 | 199.7 | 20% | 844.4 |
Operating profit (EBIT) | 6.4 | 11.3 | -43% | 46.5 |
Operating profit margin | 2.7% | 5.6% | 5.5% | |
Net result | -2.5 | 6.9 | -136% | 24.7 |
Net result margin | -1.0% | 3.4% | 2.9% | |
Basic/diluted earnings/(loss) per share, € | -0.006 | 0.046 | -113% | 0.168 |
EBITDA | 29.0 | 27.5 | 6% | 120.7 |
EBITDA margin | 12.2% | 13.8% | 14.3% | |
EBITDAaL | 16.8 | 18.5 | -9% | 80.6 |
EBITDAaL margin | 7.0% | 9.2% | 9.5% | |
EBITA | 8.9 | 12.5 | -29% | 53.7 |
EBITA margin | 3.7% | 6.3% | 6.4% |
Definition and reconciliation of alternative performance measures are available at www.medicover.com/financial-information. As from Q3 2019 margins (including margins of comparative figures) and growth rates have been calculated based on EUR whole figures instead of figures rounded in millions.
This is information that Medicover AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication through the agency of the contact person set out below at 7.45 (CEST) on 30 April 2020. This interim report and other information about Medicover is available at medicover.com.
Contact information
For further information, please contact:
Hanna Bjellquist
Head of Investor Relations
Phone: +46-70-303-32-72
E-mail: hanna.bjellquist@medicover.com
Medicover is a leading international healthcare and diagnostic services company and was founded in 1995. Medicover operates a large number of ambulatory clinics, hospitals, specialty-care facilities and laboratories and the largest markets are Poland and Germany. In 2019, Medicover had revenue around €844 million and 28,800 employees. For more information, go to www.medicover.com
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/medicover/r/interim-report-january-march-2020,c3101087
The following files are available for download:
https://mb.cision.com/Main/15662/3101087/1239343.pdf | Interim report January-March 2020 |
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Medicover AB Registered Shs -B-mehr Nachrichten
|
29.10.24 |
Ausblick: Medicover Registered B präsentiert das Zahlenwerk zum abgelaufenen Jahresviertel (finanzen.net) | |
|
15.10.24 |
Erste Schätzungen: Medicover Registered B gewährt Anlegern Blick in die Bücher (finanzen.net) | |
|
24.07.24 |
Ausblick: Medicover Registered B verkündet Quartalsergebnis zum jüngsten Jahresviertel (finanzen.net) | |
|
10.07.24 |
Erste Schätzungen: Medicover Registered B stellt Ergebnisse des abgelaufenen Quartals vor (finanzen.net) |
Analysen zu Medicover AB Registered Shs -B-mehr Analysen
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.